|
GB201317928D0
(en)
*
|
2013-10-10 |
2013-11-27 |
Ucl Business Plc |
Molecule
|
|
GB201317929D0
(en)
*
|
2013-10-10 |
2013-11-27 |
Ucl Business Plc |
Chimeric antigen receptor
|
|
EP3243831A1
(en)
*
|
2014-02-27 |
2017-11-15 |
Ucl Business Plc |
Variants of the proliferation-inducing ligand (april)
|
|
US11982672B2
(en)
|
2014-03-05 |
2024-05-14 |
Autolus Limited |
Methods
|
|
US11385233B2
(en)
|
2015-03-05 |
2022-07-12 |
Autolus Limited |
Methods of depleting malignant T-cells
|
|
GB201403972D0
(en)
|
2014-03-06 |
2014-04-23 |
Ucl Business Plc |
Chimeric antigen receptor
|
|
EP3131927B8
(en)
|
2014-04-14 |
2020-12-23 |
Cellectis |
Bcma (cd269) specific chimeric antigen receptors for cancer immunotherapy
|
|
EP3250602A1
(en)
|
2015-01-26 |
2017-12-06 |
Cellectis |
T cell receptor knock out engineered immune cells, endowed with chimeric antigen receptors binding to cd123 for the treatment of relapsed/refractory acute myeloid lymphoma or blastic plasmacytoid dendritic cell neoplasm
|
|
TWI700298B
(zh)
|
2015-04-13 |
2020-08-01 |
美商輝瑞股份有限公司 |
靶向ｂ細胞成熟抗原之嵌合型抗原受體類
|
|
GB201507108D0
(en)
*
|
2015-04-27 |
2015-06-10 |
Ucl Business Plc |
Nucleic acid construct
|
|
GB201507115D0
(en)
*
|
2015-04-27 |
2015-06-10 |
Ucl Business Plc |
Nucleic Acid Construct
|
|
GB201507111D0
(en)
*
|
2015-04-27 |
2015-06-10 |
Ucl Business Plc |
Nucleic acid construct
|
|
EP3770168A1
(en)
|
2015-05-18 |
2021-01-27 |
TCR2 Therapeutics Inc. |
Compositions and methods for tcr reprogramming using fusion proteins
|
|
MA42895A
(fr)
*
|
2015-07-15 |
2018-05-23 |
Juno Therapeutics Inc |
Cellules modifiées pour thérapie cellulaire adoptive
|
|
CA2992797A1
(en)
|
2015-08-03 |
2017-02-09 |
Engmab Sarl |
Monoclonal antibodies against bcma
|
|
CN105384825B
(zh)
*
|
2015-08-11 |
2018-06-01 |
南京传奇生物科技有限公司 |
一种基于单域抗体的双特异性嵌合抗原受体及其应用
|
|
US11090334B2
(en)
|
2016-01-29 |
2021-08-17 |
Med Manor Organics (P) Ltd. |
Chimeric antigen receptor specific to b-cell maturation antigen, a recombinant expression vector and a method thereof
|
|
EP3458091B1
(en)
|
2016-05-20 |
2021-11-17 |
Eli Lilly and Company |
Combination therapy with notch and pd-1 or pd-l1 inhibitors
|
|
US12048718B2
(en)
|
2016-06-07 |
2024-07-30 |
Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Geminschaft |
Chimeric antigen receptor and CAR-T cells that bind BCMA
|
|
WO2018026953A1
(en)
|
2016-08-02 |
2018-02-08 |
TCR2 Therapeutics Inc. |
Compositions and methods for tcr reprogramming using fusion proteins
|
|
PL3896091T3
(pl)
*
|
2016-08-10 |
2024-04-29 |
Legend Biotech Ireland Limited |
Chimeryczne receptory antygenowe nakierowane na bcma i sposoby ich zastosowania
|
|
BR112019007100A2
(pt)
|
2016-10-07 |
2019-06-25 |
Tcr2 Therapeutics Inc |
composições e métodos para reprogramação de receptores de célula t com o uso de proteínas de fusão
|
|
US11124577B2
(en)
|
2016-11-02 |
2021-09-21 |
Engmab Sàrl |
Bispecific antibody against BCMA and CD3 and an immunological drug for combined use in treating multiple myeloma
|
|
CA3042613A1
(en)
|
2016-11-11 |
2018-05-17 |
Autolus Limited |
Chimeric antigen receptor
|
|
CN110177803A
(zh)
|
2016-11-22 |
2019-08-27 |
T细胞受体治疗公司 |
用于使用融合蛋白进行tcr重新编程的组合物和方法
|
|
CN110352068A
(zh)
|
2016-12-02 |
2019-10-18 |
南加利福尼亚大学 |
合成的免疫受体及其使用方法
|
|
EP3568406A4
(en)
*
|
2017-01-10 |
2020-10-21 |
The General Hospital Corporation |
T LYMPHOCYTES EXPRESSING A CHEMERICAL ANTIGENIC RECEPTOR
|
|
IL268349B2
(en)
*
|
2017-02-17 |
2024-08-01 |
Hutchinson Fred Cancer Res |
Combination therapies for treatment of bcma-related cancers and autoimmune disorders
|
|
GB201709508D0
(en)
*
|
2017-06-15 |
2017-08-02 |
Autolus Ltd |
Chimeric antigen receptor
|
|
WO2019025800A1
(en)
*
|
2017-08-02 |
2019-02-07 |
Autolus Limited |
CELLS EXPRESSING A CHIMERIC ANTIGENIC RECEPTOR OR A MANIPULATED TCR AND COMPRISING A SELECTIVELY EXPRESSED SELECTIVE NUCLEOTIDE SEQUENCE
|
|
GB201716728D0
(en)
|
2017-10-12 |
2017-11-29 |
Autolus Ltd |
Cell
|
|
US11066475B2
(en)
|
2017-11-01 |
2021-07-20 |
Juno Therapeutics, Inc. |
Chimeric antigen receptors specific for B-cell maturation antigen and encoding polynucleotides
|
|
US11851679B2
(en)
|
2017-11-01 |
2023-12-26 |
Juno Therapeutics, Inc. |
Method of assessing activity of recombinant antigen receptors
|
|
AU2018359907A1
(en)
*
|
2017-11-06 |
2020-05-07 |
Fred Hutchinson Cancer Center |
Combination of a cell therapy and a gamma secretase inhibitor
|
|
CN119193493A
(zh)
|
2017-12-08 |
2024-12-27 |
朱诺治疗学股份有限公司 |
生产工程化t细胞组合物的过程
|
|
CN109971715A
(zh)
*
|
2017-12-28 |
2019-07-05 |
深圳华大生命科学研究院 |
一种扩增特异性car-t细胞的培养方法
|
|
CA3087476A1
(en)
*
|
2018-01-10 |
2019-07-18 |
The General Hospital Corporation |
Immune cells expressing a chimeric antigen receptor
|
|
ES2968880T3
(es)
*
|
2018-02-01 |
2024-05-14 |
Nanjing Iaso Biotechnology Co Ltd |
Receptor de antígeno quimérico (CAR) que se une a BCMA, y usos del mismo
|
|
AU2019240370B2
(en)
*
|
2018-03-23 |
2024-03-07 |
Gavish-Galilee Bio Applications Ltd. |
Genetically reprogrammed Tregs expressing membrane-bound IL-10
|
|
GB201807693D0
(en)
|
2018-05-11 |
2018-06-27 |
Autolus Ltd |
Cell
|
|
PE20210320A1
(es)
|
2018-06-01 |
2021-02-16 |
Novartis Ag |
Moleculas de union contra bcma y usos de las mismas
|
|
CA3103610A1
(en)
|
2018-06-12 |
2019-12-19 |
The Regents Of The University Of California |
Single-chain bispecific chimeric antigen receptors for the treatment of cancer
|
|
TWI838389B
(zh)
|
2018-07-19 |
2024-04-11 |
美商再生元醫藥公司 |
雙特異性抗-BCMAｘ抗-CD3抗體及其用途
|
|
SG11202102781UA
(en)
|
2018-09-27 |
2021-04-29 |
Autolus Ltd |
Chimeric antigen receptor
|
|
CN119569895A
(zh)
|
2018-11-01 |
2025-03-07 |
朱诺治疗学股份有限公司 |
G蛋白偶合受体c类5族成员d(gprc5d)特异性嵌合抗原受体
|
|
US12473345B2
(en)
|
2018-11-01 |
2025-11-18 |
Juno Therapeutics, Inc. |
Methods for treatment using chimeric antigen receptors specific for B-cell maturation antigen
|
|
GB201904160D0
(en)
|
2019-03-26 |
2019-05-08 |
Autolus Ltd |
Cell
|
|
EP3893923A2
(en)
|
2018-12-14 |
2021-10-20 |
Autolus Limited |
Cell
|
|
KR20210132668A
(ko)
*
|
2019-02-21 |
2021-11-04 |
아르벨 리미티드 |
인공 면역감시 키메라 항원 수용체(ai-car) 및 이를 발현하는 세포
|
|
GB201903237D0
(en)
|
2019-03-08 |
2019-04-24 |
Autolus Ltd |
Method
|
|
EP3934666A1
(en)
|
2019-03-08 |
2022-01-12 |
Autolus Limited |
Compositions and methods comprising engineered chimeric antigen receptor and modulator of car
|
|
KR20210143246A
(ko)
|
2019-03-21 |
2021-11-26 |
리제너론 파아마슈티컬스, 인크. |
알레르기 치료용 il-4/il-13 경로 억제제 및 형질 세포 절제의 병용
|
|
WO2020194306A1
(en)
*
|
2019-03-26 |
2020-10-01 |
Gavish-Galilee Bio Applications Ltd. |
Genetically reprogrammed tregs expressing cars
|
|
GB201904971D0
(en)
|
2019-04-08 |
2019-05-22 |
Autolus Ltd |
Cell
|
|
GB201906202D0
(en)
|
2019-05-02 |
2019-06-19 |
Autolus Ltd |
Cell
|
|
CN113784733B
(zh)
|
2019-05-07 |
2024-09-06 |
亘喜生物科技（上海）有限公司 |
靶向bcma的工程化免疫细胞及其用途
|
|
EP4778585A2
(en)
|
2019-05-07 |
2026-07-22 |
Gracell Bioscience (Shanghai) Co., Ltd. |
Engineered immune cell targeting bcma and use thereof
|
|
AU2020279224B2
(en)
|
2019-05-21 |
2024-12-05 |
Novartis Ag |
Trispecific binding molecules against BCMA and uses thereof
|
|
UY38701A
(es)
|
2019-05-21 |
2020-12-31 |
Novartis Ag |
Moléculas de unión a cd19, conjugados, composiciones que las comprenden y usos de las mismas
|
|
CN110592015A
(zh)
*
|
2019-09-27 |
2019-12-20 |
中国科学院西双版纳热带植物园 |
一种诱导增强cik细胞的滇重楼多糖组合物及其应用
|
|
WO2021113776A1
(en)
|
2019-12-06 |
2021-06-10 |
Juno Therapeutics, Inc. |
Anti-idiotypic antibodies to bcma-targeted binding domains and related compositions and methods
|
|
TW202241935A
(zh)
|
2020-12-18 |
2022-11-01 |
美商世紀治療股份有限公司 |
具有可調適受體專一性之嵌合抗原受體系統
|
|
EP4565262A2
(en)
|
2022-08-05 |
2025-06-11 |
Juno Therapeutics, Inc. |
Chimeric antigen receptors specific for gprc5d and bcma
|
|
US20250127728A1
(en)
|
2023-10-05 |
2025-04-24 |
Capstan Therapeutics, Inc. |
Constrained Ionizable Cationic Lipids and Lipid Nanoparticles
|
|
WO2025076113A1
(en)
|
2023-10-05 |
2025-04-10 |
Capstan Therapeutics, Inc. |
Ionizable cationic lipids with conserved spacing and lipid nanoparticles
|
|
WO2025160340A2
(en)
|
2024-01-26 |
2025-07-31 |
Regeneron Pharmaceuticals, Inc. |
Combination immunosuppression for inhibiting an immune response and enabling immunogen administration and re-administration
|
|
US20250242056A1
(en)
|
2024-01-26 |
2025-07-31 |
Regeneron Pharmaceuticals, Inc. |
Methods and compositions for using plasma cell depleting agents and/or b cell depleting agents to suppress host anti-aav antibody response and enable aav transduction and re-dosing
|
|
WO2025184567A1
(en)
|
2024-03-01 |
2025-09-04 |
Regeneron Pharmaceuticals, Inc. |
Methods and compositions for re-dosing aav using anti-cd40 antagonistic antibody to suppress host anti-aav antibody response
|
|
GB202403564D0
(en)
|
2024-03-12 |
2024-04-24 |
Autolus Ltd |
Method
|
|
WO2025217454A2
(en)
|
2024-04-11 |
2025-10-16 |
Capstan Therapeutics, Inc. |
Ionizable cationic lipids and lipid nanoparticles
|
|
WO2025217452A1
(en)
|
2024-04-11 |
2025-10-16 |
Capstan Therapeutics, Inc. |
Constrained ionizable cationic lipids and lipid nanoparticles
|
|
WO2026151982A1
(en)
|
2025-01-10 |
2026-07-16 |
Regeneron Pharmaceuticals, Inc. |
Methods of treating food allergy by administering an il-4r antagonist and a bcma targeting agent
|